Suppr超能文献

肿瘤大小超过5厘米是胸腺上皮肿瘤各阶段有效的预后因素。

Tumor size exceeding 5 cm as a valid prognostic factor in all stages of thymic epithelial tumors.

作者信息

Sakai Takashi, Aokage Keiju, Miyoshi Tomohiro, Tane Kenta, Ishii Genichiro, Goto Koichi, Tsuboi Masahiro

机构信息

Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.

Division of Chest Surgery, Department of Surgery, Toho University School of Medicine, Ota, Tokyo, Japan.

出版信息

Surg Today. 2023 Jan;53(1):42-50. doi: 10.1007/s00595-022-02530-7. Epub 2022 Jul 30.

Abstract

PURPOSE

This study investigated the prognostic factors of thymic epithelial tumors (TETs) to identify patients who require multidisciplinary treatment and improve the TET prognosis.

METHODS

We retrospectively reviewed the data of 268 TET patients. Prognostic variables for the overall survival (OS) were analyzed in all TET stages (n = 268), and the recurrence-free survival (RFS) was analyzed in patients who achieved complete resection (n = 164).

RESULTS

The median follow-up period was 7 years; thymic carcinomas (TCs) and advanced stages of tumor, node, and metastasis (TNM) classification had the worse prognosis according to a Kaplan-Meier analysis. The cut-off value of the tumor size to predict the OS and RFS was determined using modified Harrell's c-index calculated by a Cox regression analysis of the OS. Regarding the OS, a multivariate analysis revealed that age > 70 years old (p = 0.011), tumor size > 5 cm (p < 0.001), and TCs (p = 0.002) were significant prognostic factors aside from the TNM stage (p < 0.001). Regarding the RFS, tumor size > 5 cm was the only significant prognostic factor in the multivariate analysis (p = 0.002) aside from the TNM stage (p = 0.008).

CONCLUSIONS

Tumor size > 5 cm was shown to be a prognostic predictor in addition to the WHO and TNM classifications. Therefore, multidisciplinary treatment should be developed for TET patients with poor prognostic factors, specifically tumor size.

摘要

目的

本研究调查胸腺上皮肿瘤(TETs)的预后因素,以识别需要多学科治疗的患者并改善TETs的预后。

方法

我们回顾性分析了268例TET患者的数据。对所有TET分期(n = 268)的总生存期(OS)的预后变量进行分析,对实现完全切除的患者(n = 164)分析无复发生存期(RFS)。

结果

中位随访期为7年;根据Kaplan-Meier分析,胸腺癌(TCs)以及肿瘤、淋巴结和转移(TNM)分期的晚期预后较差。通过对OS进行Cox回归分析计算修正的Harrell's c指数,确定预测OS和RFS的肿瘤大小临界值。关于OS,多变量分析显示,除TNM分期(p < 0.001)外,年龄> 70岁(p = 0.011)、肿瘤大小> 5 cm(p < 0.001)和TCs(p = 0.002)是显著的预后因素。关于RFS,除TNM分期(p = 0.008)外,肿瘤大小> 5 cm是多变量分析中唯一显著的预后因素(p = 0.002)。

结论

除了世界卫生组织(WHO)和TNM分类外,肿瘤大小> 5 cm被证明是一个预后预测指标。因此,应针对具有不良预后因素,特别是肿瘤大小的TET患者制定多学科治疗方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验